Under terms of the deal, Samsung will provide commercial manufacturing of drug substance and drug product for AstraZeneca's biologics under development; Samsung's remuneration could increase to $545.6 million.

The arrangement will boost AstraZeneca's biologics manufacturing capabilities in the Asia Pacific region, AstraZeneca said.

PharmAbcine, Samsung Biologics expand partnership
PharmAbcine and Samsung Biologics have entered into a new strategic partnership for the development and manufacturing of PMC-403, a next-generation antibody...

AstraZeneca begins phase III trial of its COVID-19 vaccine
AstraZeneca has begun a multisite phase III clinical trial evaluation of its investigational COVID-19 vaccine, AZD1222.

Catalent to support AstraZeneca COVID-19 vaccine manufacturing
Catalent and AstraZeneca have signed an agreement to expand manufacturing support for an adenovirus vector-based COVID-19 vaccine from the University...

Samsung Biologics adds new manufacturing plant
Samsung Biologics announced that it plans to break ground on a fourth plant in South Korea this year as part of a strategy to scale up development and...

Samsung Biologics, Vir partner on SARS-CoV-2 program
Samsung Biologics announced it will manufacture Vir Biotechnology's SARS-CoV-2 monoclonal antibody program for a potential COVID-19 treatment.